Vanda Pharmaceuticals (VNDA) Non-Current Deffered Revenue (2010 - 2014)
Vanda Pharmaceuticals recorded quarterly Non-Current Deffered Revenue of $3.1 million in Q4 2014, up 6.24% quarter-over-quarter from $2.9 million in Q3 2014, and down 95.12% year-over-year from $63.5 million in Q4 2013.
Vanda Pharmaceuticals' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $3.1 million for Q4 2014.
- In Q4 2014, Non-Current Deffered Revenue fell 95.12% year-over-year to $3.1 million; the TTM figure through Dec 2014 stood at $3.1 million (down 95.12% YoY), while the FY2014 annual figure was $3.1 million, down 95.12% from the prior year.
- Non-Current Deffered Revenue came in at $3.1 million for Q4 2014 at Vanda Pharmaceuticals, up from $2.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $130.6 million in Q2 2011 to a low of $490000.0 in Q4 2010.
- A 5-year average of $48.7 million and a median of $27.4 million in 2014 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue surged 23790.61% in 2011 and slumped 98.02% in 2012, its largest moves.
- Vanda Pharmaceuticals' Non-Current Deffered Revenue stood at $490000.0 in 2010, then soared by 23790.61% to $117.1 million in 2011, then dropped by 22.88% to $90.3 million in 2012, then dropped by 29.67% to $63.5 million in 2013, then sank by 95.12% to $3.1 million in 2014.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $3.1 million, $2.9 million, and $2.9 million for Q4 2014, Q3 2014, and Q2 2014 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 3.10 Mn |
| Sep 30, 2014 | 2.92 Mn |
| Jun 30, 2014 | 2.85 Mn |
| Mar 31, 2014 | 51.76 Mn |
| Dec 31, 2013 | 63.49 Mn |
| Sep 30, 2013 | 70.24 Mn |
| Jun 30, 2013 | 3.00 Mn |
| Mar 31, 2013 | 3.02 Mn |
| Dec 31, 2012 | 90.28 Mn |
| Sep 30, 2012 | 2.80 Mn |
| Jun 30, 2012 | 2.59 Mn |
| Mar 31, 2012 | 110.46 Mn |
| Dec 31, 2011 | 117.06 Mn |
| Sep 30, 2011 | 123.82 Mn |
| Jun 30, 2011 | 130.57 Mn |
| Dec 31, 2010 | 490,000.00 |